Drug discovery starts with insightful target selection. Often target selection is a more critical driver of success than selecting the “optimal” therapeutic area. Our selection of drug targets is curated from peer-reviewed literature after an extensive analysis using defined metrics to identify targets ripe for translation. Our size and structure encourage independent thinking and our drive for quantitative rigor in analysis make us optimally suited to execute swiftly on drug discovery projects.
From an operational standpoint, our leadership is empowered to work on parallel approaches and encouraged to take decisions. We minimize cumbersome internal processes that delay advancement of projects and stress optimal experimentation and analytical thinking.
Curadev attracts passionate, creative people and builds extraordinarily productive teams. Through a careful recruiting process, Curadev has built a well-knit team of scientific investigators who thrive on the constant challenges of drug discovery research.
Curadev has a world-class scientific advisory board that works in close association with Curadev scientists to identify new research directions and accelerate Curadev’s target validation and drug discovery programs.
Curadev focuses on the creation and out-licensing of pre-IND assets and IND packages for drug development. We take a literature driven approach to identify drug targets, which are then validated in house. We consider gene knockout information, human genetic association and various types of pre-clinical data that speak to the expression and function of the target to build a model of its role in disease. An ‘out of the box’ approach to drug design helps us to rapidly establish a medchem program.
B 87, Sector 83 Noida, UP 201305 INDIA
Tel: +91-120-408 1818/19
Fax: +91-120-408 1820
For Investment, Partnering & Collaboration enquiries: email@example.com
For all other enquiries: firstname.lastname@example.org